STAT

Former Rep. Henry Waxman says lawmakers ‘derelict’ if they don’t address drug prices

Former Rep. Henry Waxman says "the balance is out of kilter right now" in the debate over drug pricing.
Former Rep. Henry Waxman spent three decades on Capitol Hill.

Henry Waxman is a household name in pharmaceutical circles — during his three decades on Capitol Hill, he helped write the Affordable Care Act and expand Medicaid and the Children’s Health Insurance Program. He sponsored the 1984 Hatch-Waxman Act, which set up the modern infrastructure for bringing generic drugs to market, and chaired the Energy and Commerce Committee, which has jurisdiction over health-related issues, from 2009 to 2011.

Since his retirement from Congress in 2015, Waxman has served as chairman of Waxman Strategies, a lobbying firm that has been active on health issues, especially the 340B drug discount program.

STAT recently sat down with Waxman to hear his thoughts on the current political landscape around drug pricing, and what his prescription is for change.

This interview has

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.
STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.

Related Books & Audiobooks